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Sirs: Sleep-wake disturbances are
common in Huntington’s disease
(HD), and include disturbances of
the sleep-wake cycle, insomnia/
disturbed night sleep with noc-
turnal awakenings, and more
rarely excessive daytime sleepi-
ness, and disturbed REM sleep [1–
3]. Furthermore, alteration of
nutrition status and energy bal-
ance (including weight loss and
altered plasma concentrations of
ghrelin and leptin) are common in
HD [4, 5].
At the present time, there are
no biochemical markers for the
diagnosis of HD.
Hypocretins (orexins) are
hypothalamic neuropeptides
which are involved in the regula-
tion of arousal, feeding behavior
and energy expenditure (i.a. via
interactions with ghrelin and
leptin). In the sleep-wake disor-
der narcolepsy-cataplexy, which is
associated with altered energy
expenditure, cerebrospinal fluid
(CSF) hypocretin-1 levels are de-
creased due to a loss of hypotha-
lamic hypocretin neurons [6, 7].
Petersen et al. recently reported a
significant loss of hypocretin
neurons and dramatically
decreased CSF hypocretin-1 levels
in the best studied rodent model
of HD [8]. Furthermore, the au-
thors observed a decrease of hyp-
ocretin-immunopositive neurons
in the hypothalamus of five human
HD patients. In our preliminary
study, therefore, we intended to
test whether CSF hypocretin-1
levels are decreased in human HD
patients.
In seven genetically confirmed
HD patients (mean age 51 years,
range 35–74 five men), we as-
sessed duration of disease (de-
fined as time from onset of first
symptom to lumbar puncture),
body mass indices and sleep-wake
disturbances by standardized
sleep questionnaires (including
Epworth Sleepiness Scale=ESS;
available in six patients). CSF
hypocretin-1 levels were deter-
mined in all patients in a single
radioimmunoassay as previously
described [9]. Levels were com-
pared with those of controls
without neurological or other
sleep-wake disorders (n=20), and
with patients with other neuro-
degenerative disorders (Parkin-
son’s disease, n=6, mean age 71
years; dementia with Lewy bodies,
n=9, mean age 73 years; Alzhei-
mer’s disease, n=7, mean age 72
years).
In the HD patients, mean
duration of disease was 4.1 years
(range 1–10). Mean BMI was 26.3
(range 22–33). Four patients re-
ported unintentional weight loss.
Sleep-wake disorders were com-
mon complaints, and included
insomnia (n=4), fragmented
night sleep without daytime
tiredness (n=1), and REM sleep
behavior disorder (n=1). Exces-
sive daytime sleepiness (defined
as ESS score>10) was not re-
ported (mean ESS score 6.3,
range 4–8).
CSF hypocretin-1 levels were
normal in all HD patients (mean
441 pg/ml, range 326–583) (Fig.
1). Levels did not differ signifi-
cantly from those of patients with
Parkinson’s disease (487 pg/ml,
range 307–654 pg/ml), dementia
with Lewy bodies (504 pg/ml,
range 382–667), and Alzheimer’s
disease (474 pg/ml, range 333–
564). There were no associations
between the presence of sleep-
wake disorders, Epworth Sleepi-
ness Scale, duration of the dis-
ease, body mass index,
unintentional weight loss, and
CSF hypocretin-1 levels.
We could not find a hypocretin
neurotransmission deficiency – as
assessed by determination of CSF
hypocretin-1 levels – in human
HD. However, Petersen et al. re-
ported an approximate 27 % loss of
hypocretin neurons in human HD
[8]. We think that this discrepancy
may be due to quantitative effects:
Gerashchenko and colleagues [10]
found that an average loss of 14 %
of rodent hypocretin neurons was
not followed by a decrease of CSF
hypocretin levels. An average loss
of 73 %, however, was associated
with a significant 50 % decline in
CSF hypocretin levels. The authors
assumed that surviving hypocretin
neurons might compensate for
hypocretin neuronal loss by in-
creased hypocretin ligand produc-
tion. Thus, interpreting Petersen’s
finding together with the observa-
tions of Gerashchenko, it is con-
ceivable that CSF hypocretin-1
levels are normal in HD
patients.
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In conclusion, we found normal
CSF hypocretin-1 levels in patients
with Huntington’s disease, inde-
pendent of the presence of sleep-
wake disorders, and independent
of nutritional status. CSF hypo-
cretin-1 determination may not be
helpful in the diagnosis of HD.
Further studies to evaluate hypo-
cretin neuronal loss in HD are
required.
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Fig. 1 CSF hypocretin-1 levels (in pg/ml) in
Huntington’s disease (HD, n=7), Parkinson’s
disease (PD, n=6), dementia with Lewy bodies
(DLB, n=9), Alzheimer’s disease (AD, n=7), and
healthy controls (Co, n=20)
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